ATTD 2021: Despite High Upfront Cost, Medtronic’s 780G Could Offer Cost Savings
In a talk at the 2021 Advanced Technologies & Treatments for Diabetes conference, Medtronic's European director of medical affairs explained how its MiniMed 780G insulin pump can reduce long-term treatment costs for diabetics.
You may also be interested in...
Medtronic’s 780G – Finally! – Gets FDA Approval
Earlier than expected, but still after a more than three year wait, the company has obtained FDA approval for its flagship insulin delivery system.
Dexcom Rumored To Be In Talks To Acquire Insulet
Dexcom may be planning to purchase Insulet to enter the insulin pump market and transform itself into a diabetes tech giant.
ATTD 2022: Mic Drop Moment As Medtronic Presents 780G Data Proving Closed Loop Ability
Results of the ADAPT study presented at the Advanced Technologies & Treatments for Diabetes conference in Barcelona support Medtronic’s hope that the 780g insulin pump will help to turn around its diabetes business or make it an attractive acquisition for another company.